CureVac Granted Manufacturing Authorization for its Third GMP Production Suite
CureVac’s GMP I, II and III Combined Production Suite Scales Up Capacity to Meet All Preclinical, Clinical and Early Launch Needs for Proprietary and Partnered Programs
CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, announced today it received the manufacturing authorization for clinical trial materials produced under Good Manufacturing Practice (“GMP”) from the competent national authority, Regierungspräsidium Tübingen (as representative of the European Medicines Agency (EMA)), for the company’s scaled up GMP III production suite. This license marks CureVac’s third production suite to manufacture at the highest standard of pharmaceutical production in the world. CureVac’s GMP I, II and III production suites are located at CureVac’s corporate headquarters campus in Tübingen, Germany.